Search

Your search keyword '"Akizuki, Keiichi"' showing total 10 results
Start Over Author "Akizuki, Keiichi" Publisher american society of hematology
10 results on '"Akizuki, Keiichi"'

1. Whole-genome landscape of adult T-cell leukemia/lymphoma

Author

Kogure, Yasunori, primary, Kameda, Takuro, additional, Koya, Junji, additional, Yoshimitsu, Makoto, additional, Nosaka, Kisato, additional, Yasunaga, Jun-ichirou, additional, Imaizumi, Yoshitaka, additional, Watanabe, Mizuki, additional, Saito, Yuki, additional, Ito, Yuta, additional, McClure, Marni B., additional, Tabata, Mariko, additional, Shingaki, Sumito, additional, Yoshifuji, Kota, additional, Chiba, Kenichi, additional, Okada, Ai, additional, Kakiuchi, Nobuyuki, additional, Nannya, Yasuhito, additional, Kamiunten, Ayako, additional, Tahira, Yuki, additional, Akizuki, Keiichi, additional, Sekine, Masaaki, additional, Shide, Kotaro, additional, Hidaka, Tomonori, additional, Kubuki, Yoko, additional, Kitanaka, Akira, additional, Hidaka, Michihiro, additional, Nakano, Nobuaki, additional, Utsunomiya, Atae, additional, Sica, R. Alejandro, additional, Acuna-Villaorduna, Ana, additional, Janakiram, Murali, additional, Shah, Urvi, additional, Ramos, Juan Carlos, additional, Shibata, Tatsuhiro, additional, Takeuchi, Kengo, additional, Takaori-Kondo, Akifumi, additional, Miyazaki, Yasushi, additional, Matsuoka, Masao, additional, Ishitsuka, Kenji, additional, Shiraishi, Yuichi, additional, Miyano, Satoru, additional, Ogawa, Seishi, additional, Ye, B. Hilda, additional, Shimoda, Kazuya, additional, and Kataoka, Keisuke, additional

Published
2022
Full Text
View/download PDF

3. Calreticulin haploinsufficiency augments stem cell activity and is required for onset of myeloproliferative neoplasms

Author

Shide, Kotaro, primary, Kameda, Takuro, primary, Kamiunten, Ayako, primary, Ozono, Yoshinori, primary, Tahira, Yuki, primary, Yokomizo-Nakano, Takako, primary, Kubota, Sho, primary, Ono, Masaya, primary, Ikeda, Kazuhiko, primary, Sekine, Masaaki, primary, Akizuki, Keiichi, primary, Nakamura, Kenichi, primary, Hidaka, Tomonori, primary, Kubuki, Yoko, primary, Iwakiri, Hisayoshi, primary, Hasuike, Satoru, primary, Nagata, Kenji, primary, Sashida, Goro, primary, and Shimoda, Kazuya, primary

Published
2020
Full Text
View/download PDF

4. Depletion of Neoplastic CD11b Positive Cells in Jak2V617F Mutant Mice Reduced Fibrocytes in Bone Marrow and Improved Myelofibrosis

Author

Ozono, Yoshinori, primary, Shide, Kotaro, primary, Kameda, Takuro, primary, Kamiunten, Ayako, primary, Tahira, Yuki, primary, Sekine, Masaaki, primary, Akizuki, Keiichi, primary, Nakamura, Kenichi, primary, Iwakiri, Hisayoshi, primary, Hidaka, Tomonori, primary, Kubuki, Yoko, primary, Hasuike, Satoru, primary, Toyoshima, Fumiyo, primary, Sawaguchi, Akira, primary, Nagata, Kenji, primary, and Shimoda, Kazuya, primary

Published
2019
Full Text
View/download PDF

5. The Role of Calreticulin in Normal Hematopoiesis and Neoplastic Hematopoiesis of Myeloproliferative Neoplasms

Author

Shide, Kotaro, primary, Kameda, Takuro, primary, Kamiunten, Ayako, primary, Ozono, Yoshinori, primary, Tahira, Yuki, primary, Sekine, Masaaki, primary, Ono, Masaya, primary, Yokomizo, Takako, primary, Kubota, Sho, primary, Akizuki, Keiichi, primary, Kubuki, Yoko, primary, Hidaka, Tomonori, primary, Sashida, Goro, primary, and Shimoda, Kazuya, primary

Published
2019
Full Text
View/download PDF

6. Haploinsufficiency of CALR Confers Hematopoietic Stem Cells (HSCs) with a Clonal Advantage over Wild-Type Cells, and, in Setting of Myeloproliferative Neoplasms, Compensates for the Functions of HSCs Impaired By the Calr Mutation

Author

Shide, Kotaro, primary, Kameda, Takuro, additional, Kamiunten, Ayako, additional, Sekine, Masaaki, additional, Ozono, Yoshinori, additional, Yokomizo, Takako, additional, Akizuki, Keiichi, additional, Tahira, Yuki, additional, Kubuki, Yoko, additional, Hidaka, Tomonori, additional, Sashida, Goro, additional, and Shimoda, Kazuya, additional

Published
2018
Full Text
View/download PDF

7. TET2 Mutation Associated with Organ Infiltrations in ATLL

Author

Kameda, Takuro, primary, Shide, Kotaro, additional, Kamiunten, Ayako, additional, Tahira, Yuki, additional, Akizuki, Keiichi, additional, Sekine, Masaaki, additional, Hidaka, Tomonori, additional, Kubuki, Yoko, additional, Hidaka, Michihiro, additional, Utsunomiya, Atae, additional, Ohshima, Takayuki, additional, Kataoka, Keisuke, additional, Ogawa, Seishi, additional, and Shimoda, Kazuya, additional

Published
2018
Full Text
View/download PDF

8. Physiological Expression of Calr Mutant Increases Cell Growth and Cytokine Independency in Human Cell Lines Expressing Mpl, and Develops Essential Thrombocythemia in Mice

Author

Shide, Kotaro, primary, Kameda, Takuro, additional, Sekine, Masaaki, additional, Kamiunten, Ayako, additional, Akizuki, Keiichi, additional, Tahira, Yuki, additional, Hidaka, Tomonori, additional, Kubuki, Yoko, additional, Honda, Arata, additional, Sawaguchi, Akira, additional, Kitanaka, Akira, additional, and Shimoda, Kazuya, additional

Published
2016
Full Text
View/download PDF

9. Mogamulizumab for ATLL in Clinical Practice

Author

Masaki Takeuchi, Kazuya Shimoda, Akira Kitanaka, Takanori Toyama, Kiyoshi Yamashita, Tomonori Hidaka, Takuro Kameda, Junzo Ishizaki, Masaaki Sekine, Seiichi Sato, Akizuki Keiichi, Kotaro Shide, Ayako Kamiunten, Yoko Kubuki, and Kouichi Maeda

Subjects
medicine.medical_specialty, Combination therapy, business.industry, Immunology, Phases of clinical research, Cell Biology, Hematology, CHOP, medicine.disease, Biochemistry, Chemotherapy regimen, Rash, Surgery, Lymphoma, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, medicine, Mogamulizumab, medicine.symptom, business, Adverse effect, medicine.drug
Abstract

Introduction Adult T-cell leukemia/lymphoma (ATLL) is an aggressive peripheral T cell neoplasm that is resistant to conventional chemotherapy and carries a poor prognosis. The effect of mogamulizumab, an immunoglobulin (Ig) G1 monoclonal antibody targeting CCR4 for ATLL cells, was reported in a previous phase 2 study in which mogamulizumab monotherapy was evaluated in relapsed ATLL patients. The overall response rate (ORR), median progression-free survival (PFS) and median overall survival (OS) were 50%, 5.2 and 13.7 months, respectively. It was not stated whether these values were derived in the real world or in clinical practice. Here we evaluate the clinical impact of mogamulizumab treatment in CCR-4-positive aggressive ATLL patients in clinical practice. Patients and methods We retrospectively analyzed 101 CCR-4-positive ATLL patients who received at least one cycle of mogamulizumab infusion between March, 2012 and April, 2016 in 7 facilities in Miyazaki prefecture, an HTLV-1 endemic area in Southwestern Japan. The ORR, PFS, OS and adverse effects (AEs) were evaluated. We next compared OS in patients with at least one course of mogamulizumab therapy with that in historical control patients without mogamulizumab therapy. Results Of the 101 patients, 92 were evaluable for treatment response, survival and AEs. The median age was 70 years old (range; 45 to 90), and 52 patients (51%) were more than 70 years old. According to Shimoyama's criteria, 66 patients were classified as acute type, 32 as lymphoma type, and 3 as chronic type. All 3 chronic-type ATLL patients had at least one unfavorable risk factor. Of the 101 patients, 96 had refractory or relapsed ATLL when mogamulizumab treatment was started, and the prior treatments consisted of VCAP-AMP-VECP, CHOP, DeVIC or CHASE therapy, with an average of 2 courses. In the 5 remaining cases, mogamulizumab was administered as the initial therapy for ATLL. Mogamulizumab was administered as monotherapy in 87 cases (86%), and as combination therapy with other drugs in 14 cases (14%). The ORR was 37%, including a complete remission rate of 19%. The median PFS and OS were 1.8 and 4.2 months, respectively. Among the 101 patients treated with mogamulizumab, only 26 (26%) fulfilled the inclusion criteria of the phase 2 clinical study. Among patients who met those inclusion criteria, the median PFS and OS were 6.0 and 8.4 months, respectively. The use of mogamulizumab improved OS in clinical practice. The median OS of patients receiving mogamulizumab therapy was 12 months, whereas that of patients who did not receive mogamulizumab in the historical cohort was 8.4 months. Hematologic toxicity and skin rash were the most common AEs, and both were manageable Conclusion Mogamulizumab therapy showed clinically meaningful activity in ATLL patients, with an acceptable toxicity in clinical practice. Disclosures No relevant conflicts of interest to declare.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results